Research Article: Habitat imaging based on DCE-MRI for differentiating luminal and non-luminal subtypes of breast cancer: a two-center study
Abstract:
To explore the application value of habitat imaging based on dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) for differentiating luminal and non-luminal subtypes of breast cancer (BC).
Retrospective data from 396 BC patients across two centers were collected. The data from Center 1 were split into a training set of 220 patients and an internal validation set of 56 patients, while Center 2 provided an external test set of 120 patients. Multivariable analysis was performed to identify independent risk factors for developing the clinical model. K-means algorithm was used to perform clustering on DCE-MRI. After feature extraction and selection, eight machine learning algorithms were utilized to build traditional radiomics model, habitat model, and clinical model. A stacking fusion strategy was employed to integrate the traditional radiomics model, habitat model, and clinical model for identifying luminal and non-luminal subtypes patients. Model performance was evaluated using receiver operating characteristic (ROC) curves, calibration curve and decision curve analysis (DCA). Shapley Additive Explanations (SHAP) was performed for model interpretability.
For the discrimination of breast cancer luminal and non-luminal subtypes, the stacking model yielded the largest area under the curve value (AUC = 0.840), followed by the habitat model and the conventional radiomics model (AUC = 0.830, AUC = 0.805, respectively), all of which were significantly better than the clinical model (p < 0.05, respectively). Calibration curves showed good calibration of the stacking model, and decision curves confirmed its favorable net clinical benefit. SHAP revealed habitat-LGBM in the stacking model with their contribution being particularly prominent.
Habitat imaging exhibits promising potential to differentiate luminal and non-luminal breast cancer subtypes. The stacking model integrating habitat-LGBM, traditional radiomics-LGBM and clinical-XGBoost may provide favorable predictive performance.
Introduction:
Breast cancer (BC) causes the leading cancer-related death in women worldwide ( 1 ). It is a biologically diverse disease with identified molecular subgroups associated with varying therapies and prognoses ( 2 ). According to the expression of the estrogen receptor (ER), progesterone receptor (PR), BC can be classified into luminal and non-luminal types ( 3 ). Overall, luminal cancers respond well to endocrine therapies and typically have a favorable prognosis. Non-luminal BC is more aggressive and has a higher…
Read more